Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.

Clinical breast cancer

Volumn 1 Suppl 1, Issue , 2000, Pages

  Kaufmann, M ^a   Bajetta, E ^a   Dirix, L Y ^a   Fein, L E ^a   Jones, S E ^a   Zilembo, N ^a   Dugardyn, J L ^a   Nasurdi, C ^a   Mennel, R G ^a   Cervek, J ^a   Fowst, C ^a   Polli, A ^a   di Salle, E ^a   Arkhipov, A ^a   Piscitelli, G ^a   Miller, L L ^a   Massimini, G ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; AROMATASE INHIBITOR; EXEMESTANE; MEGESTROL ACETATE;

AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MEGESTROL ACETATE; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 0002472662     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/cbc.2000.s.003     Document Type: Article

References (0)